Preeclampsia diagnosis aids in detecting pregnancy complications characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. These products help provide timely diagnosis and prevent adverse pregnancy outcomes. The global Preeclampsia Diagnostics Market is estimated to be valued at US$ 1587.53 Mn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The prevalence of preeclampsia has been increasing rapidly across both developed and developing regions. As per CDC, preeclampsia affects approximately 1 in 12 pregnancies worldwide. The condition poses a significant threat to health of both mother and baby if left untreated. Hence, early detection using diagnostic tests play a key role in managing the risks and improving outcomes. Rising cases have been propelling demand for various diagnosis options such as blood tests, ultrasound, and protein analysis in urine, thereby driving the preeclampsia diagnostics market growth over the forecast period. Technological advancements enabling early and accurate diagnosis will further support the positive trend.
Segment Analysis
The global preeclampsia diagnostics market is dominated by Albuminuria detection segment. This is because albuminuria or protein in urine is one of the key symptoms of preeclampsia. Detecting high levels of albumin in urine through dipsticks or urine sample analysis helps in early detection of preeclampsia. The albuminuria detection segment currently holds around 45% share of the overall market.
Key Takeaways
The Global Preeclampsia Diagnostics Market Size is expected to witness high growth over the forecast period.
Regional analysis: The preeclampsia diagnostics market in North America is expected to witness highest growth during the forecast period. Factors such as increasing incidences of preeclampsia, growing awareness about the condition, rising availability of advanced diagnostics tools and tests are driving the growth of the market in the region. The United States holds majority of the market share in North America.
Key players operating in the preeclampsia diagnostics market are The Dow Chemical Company, BASF SE, Covestro A.G., Huntsman Corp., Eastman Chemical Co., Mitsui Chemicals Inc, Recticel S.A., RTP Company Inc., Lubrizol Corp., Rampf Holding GmbH & Co. KG. These players are focusing on launching innovative and advanced diagnostics solutions to aid early detection of preeclampsia.
For More Insights, Read: https://www.newswirestats.com/preeclampsia-diagnostics-market-size-share-and-growth-forecast-2023-2030/
Related Reports: https://masstamilan.in/emerging-role-of-biosensors-in-healthcare-advancing-disease-diagnosis-and-treatment-monitoring/
Comments
0 comment